MSTN and sarcopenia: Long-term Dex treatment is known to induce muscle atrophy in myocytes by increasing the production of proteins that inhibit muscle synthesis, such as myostatin, inducing ROS production associated with mitochondrial dysfunction, and inducing apoptosis which are typical phenomena that occur during age-induced sarcopenia [41,42].